Notícias 60 Degrees Pharmaceuticals Inc - SXTP | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
60 Degrees Pharmaceuticals Inc (SXTP)
60 Degrees Pharmaceuticals Inc (SXTP) Notícias

60 Degrees Pharmaceuticals Inc (SXTP)

0,7263

-0,0737

(-9,21%)

Fechado 01 Fevereiro 6:00PM

Atrasado por 15 minutos

0,712

-0,0143

(-1,97%)

Após o horário de negociação: 9:59PM

Atrasado por 15 minutos

Capacite seu portfólio: Discussões em tempo real e ideias de negociação acionáveis.

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Form 8-K - Current report

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

Form 8-K - Current report

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

60 Degrees Pharmaceuticals

Amundi MSCI EMU Small Ca...

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições